Statements of Comprehensive Loss - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| Revenue: | |||
| License and milestone fees | $ 1,710 | $ 302 | |
| Collaborative revenue | 2,093 | 2,201 | |
| Clinical compound revenue | $ 86 | 0 | 674 |
| Total revenue | 86 | 3,803 | 3,177 |
| Operating expenses: | |||
| Research and development | 49,253 | 21,221 | 15,068 |
| General and administrative | 9,233 | 7,770 | 6,181 |
| Total operating expenses | 58,486 | 28,991 | 21,249 |
| Operating loss | (58,400) | (25,188) | (18,072) |
| Other income | 652 | 101 | 126 |
| Loss before benefit from income taxes | (57,748) | (25,087) | (17,946) |
| Benefit from income taxes | 468 | 397 | 201 |
| Net loss | $ (57,280) | $ (24,690) | $ (17,745) |
| Net loss per share: | |||
| Basic and Diluted | $ (2.10) | $ (1.00) | $ (0.85) |
| Weighted average shares: | |||
| Basic and Diluted | 27,279,008 | 24,620,372 | 20,965,935 |
| Other comprehensive income (loss), net of tax of $0: | |||
| Change in unrealized gains (losses) on available for sale marketable securities | $ 38 | $ (35) | |
| Total comprehensive loss | $ (57,242) | $ (24,725) | $ (17,745) |